key: cord-0031879-67hqt0ob authors: Clair, Benjamin D. St; Hoffman, Donna L.; McClenathan, Bruce; Banks, Taylor; Lee, Rachel U. title: Outcomes of Allergic Type Reactions Following mRNA COVID-19 Vaccination at Three Military Medical Centers date: 2022-05-19 journal: Ann Allergy Asthma Immunol DOI: 10.1016/j.anai.2022.05.010 sha: 242f52f5516c9bc1a2355b025a914da6fdb88427 doc_id: 31879 cord_uid: 67hqt0ob nan In response to the global COVID-19 pandemic two mRNA COVID-19 vaccines were developed and authorized for use 1, 2 . Adverse events following immunization (AEFI) have occurred following receipt of these vaccines to include anaphylaxis that is estimated to occur at a rate of 2.5 to 11 cases per 1 million doses 3 . Several studies have demonstrated tolerance to vaccine challenge in these individuals, suggesting the reactions are likely not IgE driven 4, 5 . The Centers for Disease Control and Prevention now considers non-severe, immediate allergic-type reactions following a dose of a COVID-19 vaccine a precaution, not a contraindication, to a subsequent dose of the same vaccine 6 . To further support the growing evidence of second dose tolerance following first dose reaction, we describe the evaluation and outcome of patients referred to three Military Health System allergy clinics for consultation for suspected allergic reactions following mRNA COVID-19 vaccination. This is a multicenter retrospective review of patients referred to the Allergy Clinics of the Walter Reed National Military Medical Center, Naval Medical Center Portsmouth, and Womack Army Medical Center, from January 2021 to November 2021 for AEFI following receipt of either mRNA COVID-19 vaccine. Those with at least one symptom consistent with an immediate hypersensitivity reaction within 24 hours of the first dose were included. The likelihood of anaphylaxis was based on the Brighton Collaboration Criteria used to determine the level of certainty of anaphylaxis 7 . Evaluation and determination of testing, vaccine challenge, or vaccine avoidance was based on the risk assessment of the evaluating allergist. Skin testing was performed to the Pfizer-BioNTech COVID-19 vaccine, polyethylene glycol (PEG), and polysorbate (PS). In the majority of cases the vaccine and component testing was done with full strength prick test followed by 1:100 dilution intradermal 8 . Vaccine challenge was offered to most patients at full dose, except for three patients who received split dosing at the discretion of the treating allergist. Premedication was not routinely used. The Institutional Review Board at WRNMMC determined this was exempt from IRB review. There were 391 patients referred for concern of an AEFI following either mRNA COVID-19 vaccine. Sixty-five patients met inclusion criteria. The majority of patients included in the study were female (78%) and the mean age was 42 years (13-78 years). Fifty-eight (88%) of patients received the Pfizer-BioNTech COVID-19 vaccine. Twenty-seven (42%) patients met Brighton level 1-3 classification, see Table 1 . The primary symptoms reported were sensation of throat closure (45%), pruritus (31%), lightheadedness (30%), flushing (27%), urticaria (24%), shortness of breath (19%), nausea (16%), angioedema (9%), tachycardia (4%), hoarse voice (4%), or a combination. Twenty-six (40%) patients underwent skin prick testing. One patient (4%) was skin test positive to the Pfizer COVID-19 vaccine on intradermal testing at 1:100, all other skin testing was negative; this patient was advised against the second dose. In terms of second dose recommendations, 7 (11%) were advised against by the allergist, 5 (8%) declined, and 53 (82%) underwent vaccine challenge. Forty-seven (89%) who underwent vaccine challenge had no symptoms, while 6 (11%) experienced recurrence of symptoms. One patient received a 10% dose and within minutes developed throat clearing, sensation of throat closure, ear fullness, but with normal vitals and received epinephrine with quick resolution of symptoms. The remaining 90% of the vaccine dose was withheld. Two patients had mild self-resolved pruritus and urticarial rash. Three described isolated throat closure sensation with normal vitals and no resipiratory distress; real-time laryngoscopy revealed pharyngeal muscle tension without evidence of edema most consistent with vocal cord dysfunction. Our study showed that nearly 90% of patients with first dose allergic symptoms tolerated the second dose with no recurrence of symptoms and all but one had symptoms that were mild and self-limited. The majority of reactions in our study were self-reported symptoms without objective findings of anaphylaxis. A few examples of this were illustrated in the three patients with sensation of throat closure following vaccine challenge with evidence of vocal-cord dysfunction on real-time laryngoscopy without respiratory distress or vital sign abnormalities. This is particularly relevant given the primary symptom patients in our study reported was sensation of throat closure. The role for skin testing appears to be limited as 96% of the patients were skin test negative and almost 88% of patients tolerated vaccine challenge, hence these cases do not appear to be IgEmediated 9 . One patient did have a positive intradermal test at 1:100 concentration of the mRNA vaccine. She was advised against receiving the second dose; therefore it is unclear if she was truly allergic or only sensitized as there has been published data of patients with both a clinical allergic reaction and positive skin testing who tolerated a subsequent dose 10 . This is further illustrated by the patient with objective signs of an allergic reaction on vaccine challenge and received epinephrine, but was skin test negative. Despite the rarity of IgE-mediated allergy to the mRNA COVID-19 vaccines and growing evidence of 2 nd dose tolerance, 12 (18%) patients in our cohort either declined or were advised against receiving the 2 nd dose. However, as the vaccination campaign progressed, more patients who presented with similar clinical concerns were offered a vaccine challenge highlighting the important role of an allergist in improving patient comfort following allergic type reactions to these vaccines. Nearly half of the cohort met Brighton criteria for vaccine anaphylaxis. More patients in this group received epinephrine as part of the treatment for their index reaction, were advised against receiving the second dose, and were skin tested. However, the vast majority of this cohort, at all levels of certainty of vaccine anaphylaxis, tolerated vaccine challenge without recurrence of symptoms or had mild self-resolved symptoms. In summary, this study demonstrates that most patients with reported symptoms of allergic reactions to the mRNA COVID-19 vaccines can tolerate the second dose. Skin testing does not appear to be effective at predicting second dose reactions. These reactions can lead to vaccine hesitancy and incomplete vaccination, hence these studies are critical to supporting the vaccination effort. Further studies are needed to understand mechanisms of AEFI following mRNA COVID-19 vaccinations. Immediate allergic symptoms 6 (12)* *One subject was treated with epinephrine after administration of 10% dose with quick symptom resolution. Two patients had mild self-resolved pruritus and urticarial rash. Three experienced sensation of throat closure and realtime laryngoscopy revelaed pharyngeal muscle tension without evidence of edema. Pfizer-BioNTech COVID-19 vaccine Moderna COVID-19 vaccine Reports of Anaphylaxis After Receipt of mRNA COVID-19 Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine Adverse reactions to vaccines practice parameter 2012 update First Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing Graded Administration of Second Dose of Moderna and Pfizer-BioNTech COVID-19 mRNA Vaccines in Patients With Hypersensitivity to First Dose The authors thank FNP Laurie Housel and Dr. Jay Montgomery for their efforts in data retrieval and editorial and writing support.